LAYERBIO
LayerBio is developing novel drug delivery solutions to unmet medical needs in wound care, orthopedics and other therapeutic areas. Its unique LayerForm technology is based on propriety layer-by-layer (LbL) fabrication techniques developed at Massachusetts Institute of Technology (MIT). It was founded in 2013 and is headquartered in Arlington, Massachusetts.
LAYERBIO
Social Links:
Industry:
Biotechnology Delivery Service Health Care Medical Therapeutics
Founded:
2013-01-01
Address:
Arlington, Massachusetts, United States
Country:
United States
Website Url:
http://www.layerbio.com
Total Employee:
1+
Status:
Active
Contact:
617-453-8210
Email Addresses:
[email protected]
Total Funding:
384.96 K USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Organization Schema Office 365 Mail
Current Employees Featured
Founder
Investors List
National Science Foundation
National Science Foundation investment in Grant - LayerBio
Official Site Inspections
http://www.layerbio.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "LayerBio"
LayerBio
LayerBio is developing novel therapies to address unmet needs in the field of ophthalmology.See details»
LayerBio - Crunchbase Company Profile & Funding
LayerBio is developing novel drug delivery solutions to unmet medical needs in wound care, orthopedics and other therapeutic areas. Its unique LayerForm technology is based on …See details»
LayerBio Company Profile 2024: Valuation, Funding & Investors
Developer of novel therapies intended to address unmet needs in the field of ophthalmology.See details»
LAYERBIO, INC. Company Profile | Lexington, MA | Competitors ...
Find company research, competitor information, contact details & financial data for LAYERBIO, INC. of Lexington, MA. Get the latest business insights from Dun & Bradstreet.See details»
LayerBio, Inc - LinkedIn
LayerBio, Inc | 204 followers on LinkedIn. LayerBio, Inc. is developing its proprietary LayerFormâ„¢ drug delivery technology for application in ophthalmology, wound care and other therapeutic...See details»
LayerBio - VentureRadar
Website: http://www.layerbio.com/ Develops novel ophthalmology therapies using bioerodible sustained-release technology, OcuRingâ„¢, for cataract surgery in collaboration with MIT's Dr. …See details»
LayerBio Awarded $3M from U.S. Department of Defense (DoD) to …
Jul 1, 2020 · LayerBio today announced receipt of a $3 million Technology/Therapeutic Development Award (TTDA) from the U.S. Department of Defense (DoD) through the …See details»
LayerBio Awarded $3M From U.S. Department of …
Jul 1, 2020 · LayerBio today announced receipt of a $3 million Technology/Therapeutic Development Award (TTDA) from the U.S. Department of Defense (DoD) through the Congressionally Directed Medical Research...See details»
LayerBio - Org Chart, Teams, Culture & Jobs - The Org
View LayerBio's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
LayerBio - Crunchbase
LayerBio develops a proprietary LayerForm drug delivery technology for application in ophthalmology.See details»
LayerBio - Contacts, Employees, Board Members, Advisors & Alumni
LayerBio develops a proprietary LayerForm drug delivery technology for application in ophthalmology.See details»
LayerBio - Overview, News & Similar companies | ZoomInfo.com
Jul 1, 2020 · LayerBio contact info: Phone number: (678) 427-2334 Website: www.layerbio.com What does LayerBio do? About LayerBio: LayerBio, Inc. is clinical-stage biotechnology …See details»
LayerBio - Deshpande Center for Technological Innovation
LayerBio is developing a biodegradable nanoparticle drug delivery system for sustained release of an existing FDA-approved glaucoma drug. It will be delivered through a simple office-based …See details»
LayerBio Granted U.S. Patent for OcuRingâ„¢ Drug Delivery Platform
Dec 1, 2021 · LayerBio's lead product candidate OcuRing-Kâ„¢ is a sustained-release nonsteroidal anti-inflammatory drug (NSAID) formulation of ketorolac, an opioid-sparing analgesic with …See details»
LayerBio granted patent for novel drug delivery platform
Dec 2, 2021 · According to Kenneth Mandell, MD, PhD, CEO and founder of LayerBio, the patent issuance marks a key milestone for the drug delivery platform, which is a novel bioerodible …See details»
MIT Spinoff Receives NSF Grant to Develop Nanoparticle …
Dec 11, 2014 · LayerBio is an MIT spin-off developing novel drug delivery products for ophthalmology and wound care applications. The National Science Foundation (NSF) has …See details»
LayerBio Granted U.S. Patent for OcuRingâ„¢ Drug Delivery
Dec 1, 2021 · LayerBio's lead product candidate OcuRing-Kâ„¢ is a sustained-release nonsteroidal anti-inflammatory drug (NSAID) formulation of ketorolac, an opioid-sparing analgesic with …See details»
LayerBio | VentureRadar
Website: http://www.layerbio.com/ Develops novel ophthalmology therapies using bioerodible sustained-release technology, OcuRingâ„¢, for cataract surgery in collaboration with MIT's Dr. …See details»
LB-100(Layerbio) - Drug Targets, Indications, Patents - Synapse
LB-100(Layerbio), Initially developed by Layerbio, Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Eye Diseases, Active Indication: Glaucoma, Active Org.: …See details»
LB 100 - Layerbio - AdisInsight - Springer
Apr 15, 2021 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. LB 100 is being developed by Layerbio (an Massachusetts …See details»